Keros Therapeutics, Inc. (KROS)

Keros Therapeutics' stock was impacted by several key events. The stock price plummeted in December 2024 after halting high-dose arms in its Phase 2 TROPOS trial for cibotercept (KER-012) due to safety concerns. Prior to the trial halt, Keros Therapeutics signed a licensing agreement with Takeda Pharmaceutical Company Limited for elritercept (KER-050). Keros Therapeutics presented additional clinical data from its KER-065 program at the American Society of Bone and Mineral Research 2025 Annual Meeting in September 2025 and from its rinvatercept program at the 2026 MDA Clinical & Scientific Conference. Keros Therapeutics participated in several healthcare conferences in early 2026. Keros Therapeutics reported a Q4 loss of $0.86 per share, missing estimates, and revenue was down 87.2% compared to the same quarter last year.

Keros Therapeutics, Inc. does not typically experience demand seasonality for its products and services. Its revenue and operational focus are primarily driven by research and development milestones, clinical trial progress, regulatory approvals, and potential commercialization of its drug candidates.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for hematological, pulmonary, and cardiovascular disorders. The company modulates the transforming growth factor-beta (TGF-β) family of proteins. Elritercept (KER-050) is being developed for low blood cell counts and has been licensed to Takeda Pharmaceuticals (excluding China). Rinvatercept (KER-065) is a neuromuscular candidate for Duchenne muscular dystrophy. KER-012 (cibotercept) is being developed for pulmonary arterial hypertension (PAH) and other cardiovascular disorders.

Keros Therapeutics, Inc. is headquartered in Lexington, Massachusetts, United States. The company conducts global Phase 3 clinical trials for elritercept (KER-050), with activities across North America and Europe.

Keros Therapeutics' brand reputation was significantly affected by the safety setback in its Phase 2 TROPOS trial for KER-012 in December 2024. The voluntary halt of high-dose arms led to a substantial drop in the company's stock price. The partnership with Takeda Pharmaceutical Company for elritercept provides financial stability. Analyst consensus for Keros Therapeutics is generally a "Hold," reflecting a mixed view on the company's prospects.

Keros Therapeutics, Inc. is primarily owned by institutional shareholders, who hold 101.81% of the stock, and Keros Therapeutics insiders, who hold 45.83%. Retail investors hold 0.00%. As of April 10, 2026, there are 174 institutional owners and shareholders holding a total of 20,284,057 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Arrowstreet Capital, Limited Partnership, State Street Corp, Madison Avenue Partners, LP, Orbimed Advisors Llc, Qube Research & Technologies Ltd, Jacobs Levy Equity Management, Inc., D. E. Shaw & Co., Inc., and Federated Hermes, Inc. The largest individual shareholder is Alon Lazarus, who owns 2.04 million shares, representing 10.33% of the company.